mufa 22:1

MUFA 22:1 is a term used to describe a class of very long‑chain monounsaturated fatty acids with 22 carbon atoms and one double bond. The best‑studied compound in this category is erucic acid (cis‑13‑docosenoic acid), an omega‑9 monounsaturated fatty acid. Chemically, MUFAs are fatty acids with a single double bond, differentiating them from saturated and polyunsaturated fatty acids. Erucic acid is found in plants of the Brassicaceae family, especially in high concentrations in mustard oil, rapeseed oils from non‑canola varieties, and, to a lesser extent, in various seafood oils. In food composition databases, 22:1 MUFAs may be reported as the sum of different isomers, including erucic and cetoleic acids, which are positional isomers. While common dietary MUFAs such as oleic acid have well‑recognized roles in nutrition and cardiovascular health, MUFA 22:1 compounds like erucic acid have a more complex profile. Historically, interest in erucic acid dates to studies in the 1970s and 1980s that observed lipid accumulation in animal hearts after very high intakes, leading to safety evaluations and breeding of low‑erucic acid rapeseed (canola) varieties. In humans, definitive roles for MUFA 22:1 in health and disease have not been established, and regulatory bodies do not set dietary reference intakes for this nutrient. Research in vitro and in animal models suggests that 22:1 fatty acids may influence fatty acid metabolism, including peroxisomal beta‑oxidation and the synthesis of other long‑chain fatty acids, but clear evidence of beneficial effects in humans is limited.

As a long‑chain monounsaturated fatty acid, MUFA 22:1 serves primarily as a structural and energetic component within lipids. In biochemical pathways, very long‑chain fatty acids are integrated into triglycerides and phospholipids, contributing to membrane composition and energy storage. Research suggests that specific 22:1 MUFAs, such as cetoleic acid, may influence the metabolic pathway for synthesizing n‑3 long‑chain polyunsaturated fatty acids like EPA and DHA, potentially by enhancing peroxisomal beta‑oxidation processes. For example, a study in human hepatocytes and salmon hepatocytes found that increased cetoleic acid levels in cells led to a 40% increase in the conversion of alpha‑linolenic acid to EPA and DHA in vitro and improved retention of these long‑chain omega‑3 fatty acids in salmon after dietary intake. However, such findings are preliminary and predominantly from cell culture and animal models. Unlike well‑established MUFAs such as oleic acid—which have documented cardiovascular benefits including improvements in lipid profiles and modest anti‑inflammatory effects—evidence for specific benefits of erucic acid in human nutrition is sparse. Much of the literature on long‑chain MUFAs focuses on their presence in dietary fats and potential metabolic effects rather than well‑defined clinical endpoints. Moreover, some early animal studies raised concerns about potential adverse effects of high erucic acid intake, particularly on cardiac tissue lipid accumulation, although these effects have not been demonstrated in humans. Overall, while MUFA 22:1 compounds are part of the broader category of monounsaturated fats that contribute to dietary fat intake, specific health benefit claims for this nutrient are not established and require more research to substantiate any unique functions beyond general fatty acid metabolism.

There are no established dietary reference intakes (DRIs) or recommended daily allowances (RDAs) for MUFA 22:1 from authoritative bodies such as the NIH Office of Dietary Supplements. Unlike essential fatty acids such as linoleic and alpha‑linolenic acids—which have defined adequate intake levels due to their roles in physiological function—erucic acid and other 22:1 MUFAs are not considered essential. Typical dietary intake of 22:1 fatty acids occurs through consumption of certain plant oils, such as mustard oil, and seafood, particularly oily fish and fish oils, where they contribute variable amounts to total fatty acid intake. Because no formal intake recommendations exist, there is no clear threshold for optimal versus minimum intake. Regulatory agencies have instead focused on safety considerations. For example, the European Food Safety Authority (EFSA) has assessed tolerable daily intake based on animal data due to concerns over high levels producing cardiac effects in animal models. In practice, most dietary guidance emphasizes overall dietary fat quality rather than intake of specific minor fatty acids. Recommendations for total monounsaturated fat intake—such as those in Mediterranean‑style diets—focus on replacing saturated and trans fats with healthier fats from olive oil, nuts, seeds, and fish. These dietary patterns, rich in oleic acid and other MUFAs, are associated with favorable cardiovascular outcomes. While erucic acid is part of the MUFA spectrum, its contribution to health outcomes remains unclear, and there is no evidence to support specific targets. Individuals consuming balanced diets that include a variety of plant oils and seafood will typically ingest low to moderate amounts of 22:1 MUFAs as part of overall fat intake without needing to monitor this nutrient specifically.

Because MUFA 22:1 compounds like erucic acid are not considered essential fatty acids, there is no recognized deficiency syndrome attributable to inadequate intake of this specific nutrient. Essential fatty acids are defined by the requirement for dietary intake to maintain physiological function; examples include linoleic and alpha‑linolenic acids. MUFA 22:1 does not fall into this category, and humans can synthesize a wide range of monounsaturated fatty acids from other fatty acid precursors. Consequently, there are no specific signs or clinical symptoms of MUFA 22:1 deficiency documented in the medical literature. Reports of Mead acid (20:3 n‑9) accumulation, for example, indicate essential fatty acid deficiency in severe cases where both linoleic and alpha‑linolenic acid are lacking, but this does not pertain specifically to 22:1 MUFAs. In experimental animals, extremely high intake of erucic acid can lead to cardiac lipidosis and changes in lipid metabolism, but this is a toxicity effect rather than a deficiency. As a result, there are no established blood test markers or deficiency disease states for MUFA 22:1, and clinical assessment does not include measures of this individual fatty acid. Instead, clinicians assess overall fatty acid status through lipid profiles, essential fatty acid ratios, and biomarkers related to cardiovascular and metabolic health when evaluating nutritional status. Thus, while consumption of a balanced diet rich in a variety of fats supports overall health, there is no clinical framework for identifying or treating a deficiency of MUFA 22:1 specifically.

MUFA 22:1 fatty acids, predominantly erucic acid and positional isomers like cetoleic acid, occur in a range of plant oils and seafood products. Plant sources typically have the highest concentrations, particularly oils derived from seeds of plants in the Brassicaceae family. Mustard oil is one of the richest dietary sources of erucic acid, with levels reported up to approximately 41 grams per 100 grams of oil. Traditional rapeseed oil from non‑canola varieties also contains high amounts, although modern canola oil varieties are selectively bred to have very low erucic acid content for safety reasons. Other seeds, such as mustard seed itself, provide smaller but significant amounts of 22:1 MUFAs. Seafood is another key category; oily fish and fish oils contain 22:1 MUFAs as part of their complex fatty acid profiles. Herring fish oil, cod liver oil, sardine oil, salmon fish oil, and various preparations of oily fish such as pickled herring, dried sardines, and mackerel provide measurable amounts of 22:1 MUFAs. It is important to note that the specific data from food composition databases often combine all 22:1 fatty acids without distinguishing between isomers, so reported values represent total 22:1 content. Foods with notable amounts per 100 grams include mustard oil (~41.2 g), herring fish oil (~20.6 g), mustard seed (~9.4 g), cod liver fish oil (~7.3 g), spotted seal oil (~5.9 g), sardine fish oil (~5.6 g), pickled herring (~4.1 g), beluga oil (~3.5 g), salmon fish oil (~3.4 g), and various dried or cooked oily fish ranging from approximately 1.7 g to 2.6 g. These foods illustrate that while 22:1 MUFAs are present in the diet, their intake is highly variable and often represents a small fraction of total fat intake compared to more abundant fatty acids like oleic, linoleic, and alpha‑linolenic acids. As with all dietary fat intake, consideration of overall fat quality and balance with other nutrients is critical. The inclusion of a variety of fish and plant oils within a balanced diet can contribute to a spectrum of fatty acids, including MUFA 22:1, without the need to target this specific nutrient.

Dietary fatty acids, including MUFA 22:1, are absorbed in the small intestine through processes involving emulsification by bile salts, enzymatic digestion by pancreatic lipases, and incorporation into micelles. These micelles allow long‑chain fatty acids to be taken up by enterocytes, where they are re‑esterified into triglycerides and packaged into chylomicrons for transport through the lymphatic system into circulation. The efficiency of absorption for very long‑chain fatty acids like 22:1 MUFAs is generally high, similar to other long‑chain fatty acids, although subtle differences in chain length and the position of double bonds can influence enzymatic handling and metabolic fate. Bioavailability is also impacted by the food matrix; fats consumed as part of oil or fatty fish are readily absorbed, whereas fats within complex matrices may be modestly less accessible. Absorption can be enhanced by the presence of other dietary fats, as mixed micelle formation is more efficient when a variety of lipid species are present. Conversely, factors that interfere with fat digestion—such as cholestasis, pancreatic insufficiency, or use of bile acid sequestrants—can reduce absorption of all dietary fats, including MUFA 22:1. Once absorbed, fatty acids are distributed to tissues via lipoproteins, with incorporation into cellular membranes and storage in adipose tissue. Enzymatic pathways in the liver and peripheral tissues can further metabolize very long‑chain fatty acids; for instance, peroxisomal beta‑oxidation plays a role in shortening chains like those of 22:1 fatty acids to forms that can enter mitochondrial oxidation pathways. Although food sources rich in MUFAs such as oleic acid have documented beneficial effects on lipid profiles and insulin sensitivity, specific data on bioavailability differences unique to 22:1 fatty acids are limited. Overall, inclusion of dietary fats as part of balanced meals supports efficient absorption and utilization of a range of fatty acids.

There are currently no established recommendations for supplementation with MUFA 22:1 fatty acids such as erucic acid. Unlike essential fatty acids (e.g., omega‑3 and omega‑6) for which supplements may be beneficial in certain populations, 22:1 MUFAs are not required to prevent deficiency and do not have well‑defined clinical benefits that warrant routine supplementation. Most individuals obtain MUFA 22:1 through dietary intake of plant oils and seafood, often as minor components of broader fat consumption. While some niche products may include oils with higher 22:1 content, such as traditional mustard oil, the trend in food oil production has been toward low‑erucic acid cultivars like canola to minimize potential safety concerns. Research on potential benefits of long‑chain MUFAs, including cetoleic acid, suggests possible influences on fatty acid metabolism and synthesis pathways, but evidence in humans is preliminary and does not support targeted supplementation. As a result, healthcare professionals generally do not recommend supplements specifically for MUFA 22:1, focusing instead on established fats and oils that contribute beneficial fatty acids such as oleic acid, EPA, and DHA. Individuals considering any supplement should consult with a healthcare provider, especially those with underlying health conditions or taking medications that affect fat metabolism. Quality, purity, and safety of supplements should be evaluated, and products should be sourced from reputable manufacturers that provide third‑party testing. Given the lack of clear evidence for benefit and the potential for harm at very high intake levels suggested by animal studies, supplementation with MUFA 22:1 is not widely advised.

Although humans consume MUFA 22:1 fatty acids as part of diets that include plant oils and seafood, concerns about toxicity stem primarily from animal studies where extremely high intakes of erucic acid led to cardiac lipid accumulation and related effects. In rats and other experimental animals, high levels of erucic acid in the diet have been associated with lipidosis characterized by accumulation of triglycerides in heart tissue, likely due to inefficient mitochondrial oxidation of very long‑chain fatty acids. These findings prompted regulatory scrutiny in the past and contributed to breeding of low‑erucic acid rapeseed varieties (canola) for human food use. Regulatory bodies such as the European Food Safety Authority have evaluated tolerable daily intake (TDI) levels based on animal data, suggesting limits such as 7 mg/kg body weight per day to minimize risk, although these values are conservative and derived from extrapolation rather than observed human toxicity. No formal tolerable upper intake level (UL) has been established by NIH or other major dietary reference organizations. Human data on toxicity are limited, and adverse effects have not been conclusively documented at dietary exposure levels typical in populations consuming varied diets. However, caution is warranted with concentrated sources such as certain traditional oils with high erucic acid content, and regulatory standards have historically limited levels of this fatty acid in food oils. Signs of excessive intake in experimental models include cardiac lipidosis and related functional impairments, but such outcomes have not been systematically observed in humans. Overall, toxicity concerns for MUFA 22:1 center around very high exposures rather than amounts obtained through typical dietary patterns. Consumption of a balanced diet that emphasizes a variety of fats, particularly those with established health benefits like oleic, omega‑3, and omega‑6 fatty acids, is recommended over focusing on high intake of specific long‑chain MUFAs.

There is limited evidence regarding specific interactions between MUFA 22:1 fatty acids and medications. As a dietary fat component, its metabolism may intersect with pathways that drugs affecting lipid metabolism target. For example, medications that influence lipid absorption, such as bile acid sequestrants, could modestly affect absorption of all dietary fats, including 22:1 MUFAs, by interfering with micelle formation. Drugs that modulate peroxisomal or mitochondrial fatty acid oxidation, such as fibrates or certain investigational agents, may theoretically interact with the metabolism of very long‑chain fatty acids due to shared enzymatic pathways, but direct evidence of clinically relevant interactions specific to MUFA 22:1 is lacking. Individuals taking medications that significantly alter lipid digestion or transport should discuss dietary fat intake with their healthcare provider to optimize overall nutrition. At present, no specific drug‑nutrient interactions have been established that necessitate adjustment of MUFA 22:1 intake beyond general recommendations for healthy fat consumption in the context of prescribed therapies.